Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 30 min ago
PreprintCC BY-NCbioRxiv

A Ribosomal RNA modification regulates translation of PI3K/AKT activators in high-grade serous ovarian carcinoma

  1. 1Universite de Sherbrooke

Abstract

PI3K/AKT signalling is a key driver of ovarian cancer progression and an important therapeutic target. Its deregulation is usually explained by genetic changes and altered signalling at the cell surface. Here, we identify an additional layer of pathway control, in which a change in the level of a cancer-associated ribosomal RNA modification alters the translation of proteins that regulate PI3K/AKT activity. SNORA81 is a high-grade serous ovarian carcinoma-associated H/ACA small nucleolar RNA that directs pseudouridylation of 28S ribosomal RNA at position U4636. Integration of tumour transcriptomes with independent SNORA81-depletion datasets identified 22 SNORA81-linked transcripts with reversed disease-associated expression, 19 of them linked to PI3K/AKT signalling. SNORA81 depletion reduced AKT phosphorylation, impaired cell growth, migration, and altered cell-cycle distribution. Molecularly, polysome profiling following SNORA81 depletion identified 524 mRNAs with altered ribosome association, 485 of which changed independently of RNA abundance and included 29 PI3K/AKT regulators. SNORA81 depletion reduced ribosome association of ITGB4, RASGRP2, IGF1 and FGF18 transcripts, and reduced ITGB4 and RASGRP2 protein abundance. IRAK1 and SPC24 acted as downstream RNA-response genes contributing to selected SNORA81-associated phenotypes. ITGB4 expression partially restored cell growth and restored downstream RNA responses after SNORA81 depletion. These findings identify rRNA modification as a translational regulator of PI3K/AKT signalling in ovarian cancer.

Related

  1. A ribosomal pseudouridine drives an oncogenic translation program
    L. Faucher-Giguere, A. Rivera-Pizana, B. Seguineau de Preval +9
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  2. THE MULTIFUNCTIONAL PROTEIN E4F1 REGULATES MELANOCYTIC FUNCTIONS IN MICE THROUGH PROTEIN TRANSLATION AND MITF EXPRESSION
    M. Rousseau, M. Houdeville, L. Henry +18
    bioRxivPreprintAll rights reservedFull textPhysiologybioRxiv
  3. The Toxic Effects and Mechanism of Acetamiprid Exposure on Testicular Tissue: ALKBH5 Regulates m⁶A Modification to Affect PI3K-AKT-Mediated Apoptosis.
    Xiaoyan Hua, Yubin Li, Lixiang Pang +9
    ToxicsPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC
  4. Sentinel lymph node-guided modification of postoperative radiotherapy in oral tongue squamous cell carcinoma: a retrospective dosimetric and NTCP modelling study.
    Einar Björgvinsson, Aeneas Kolev, Eva Onjukka +7
    Clinical and translational radiation oncologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. METTL1-mediated m⁷G modification regulates hair follicle cycle via the HOXC13/FOXN1/DSG4 axis
    Xinyan Gan, Qiwen Li, Qiuchan Xiong +8
    PLOS GeneticsPeer-reviewedCC BY 4.0Full textPhysiologyPLOS
BibTeX
@misc{pizana2026ribosomal,
  title = {{A Ribosomal RNA modification regulates translation of PI3K/AKT activators in high-grade serous ovarian carcinoma}},
  author = {A. Rivera Pizana and L. Faucher-Giguere and M. S. Scott and S. Abou Elela},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.06.757003},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.06.757003v1},
  note = {CC BY-NC},
}
RIS
TY  - UNPB
TI  - A Ribosomal RNA modification regulates translation of PI3K/AKT activators in high-grade serous ovarian carcinoma
AU  - A. Rivera Pizana
AU  - L. Faucher-Giguere
AU  - M. S. Scott
AU  - S. Abou Elela
PY  - 2026
DA  - 2026/10/06
PB  - bioRxiv
DO  - 10.64898/2026.10.06.757003
UR  - https://www.biorxiv.org/content/10.64898/2026.10.06.757003v1
AB  - PI3K/AKT signalling is a key driver of ovarian cancer progression and an important therapeutic target. Its deregulation is usually explained by genetic changes and altered signalling at the cell surface. Here, we identify an additional layer of pathway control, in which a change in the level of a cancer-associated ribosomal RNA modification alters the translation of proteins that regulate PI3K/AKT activity. SNORA81 is a high-grade serous ovarian carcinoma-associated H/ACA small nucleolar RNA that directs pseudouridylation of 28S ribosomal RNA at position U4636. Integration of tumour transcriptomes with independent SNORA81-depletion datasets identified 22 SNORA81-linked transcripts with reversed disease-associated expression, 19 of them linked to PI3K/AKT signalling. SNORA81 depletion reduced AKT phosphorylation, impaired cell growth, migration, and altered cell-cycle distribution. Molecularly, polysome profiling following SNORA81 depletion identified 524 mRNAs with altered ribosome association, 485 of which changed independently of RNA abundance and included 29 PI3K/AKT regulators. SNORA81 depletion reduced ribosome association of ITGB4, RASGRP2, IGF1 and FGF18 transcripts, and reduced ITGB4 and RASGRP2 protein abundance. IRAK1 and SPC24 acted as downstream RNA-response genes contributing to selected SNORA81-associated phenotypes. ITGB4 expression partially restored cell growth and restored downstream RNA responses after SNORA81 depletion. These findings identify rRNA modification as a translational regulator of PI3K/AKT signalling in ovarian cancer.
ER  -